Exelixis, Inc. (EXEL)
65.86
-2.44
(-3.57%)
USD |
NASDAQ |
Nov 19, 16:00
65.86
0.00 (0.00%)
After-Hours: 16:26
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 16.11B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 60.12% |
| Valuation | |
| PE Ratio | 19.71 |
| PE Ratio (Forward) | |
| PS Ratio | 6.983 |
| Price to Book Value | 8.787 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0884 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 53.09% |
Profile
| Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA. |
| URL | http://www.exelixis.com |
| Investor Relations URL | https://ir.exelixis.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Core |
| Next Earnings Release | Feb. 09, 2027 (est.) |
| Last Earnings Release | Oct. 29, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA. |
| URL | http://www.exelixis.com |
| Investor Relations URL | https://ir.exelixis.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Core |
| Next Earnings Release | Feb. 09, 2027 (est.) |
| Last Earnings Release | Oct. 29, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |